Health Economics Consulting
Turn your reimbursement pathway into something investors and payers can believe.
We build the economic case for health tech companies raising capital, entering new markets, or preparing reimbursement submissions. Evidence that holds up to payer and investor scrutiny.
Health economics has moved to the front of the roadmap.
It now shapes pricing, trial design, and investor conversations, all of which get harder to reverse the longer they wait.
Investors are asking earlier.
Series A and B diligence now routinely includes reimbursement pathway questions. Companies that cannot answer them confidently leave value on the table.
Consultancies hand you files you cannot defend without them.
Traditional health economics deliverables are closed Excel or TreeAge models. When an investor asks a question and the economist is not in the room, the model becomes a liability.
In-house health economics is premature.
A full-time health economics hire makes sense at scale. Before that point, a fractional team gives you the same capability without the overhead.
How we work
We make your team fluent in your own economics.
Your team works on the model with us from the start. They know how every assumption was chosen and what happens if it changes. When we step back, they can run scenarios, brief investors, and stand behind the numbers on their own.
Jurisdiction-aware from day one.
We work across the United States, Europe, Asia, Australia, and New Zealand. The model is built for multi-market expansion from the outset.
A live model you can interrogate.
Engagements run on HEX Platform™. Every parameter has a source, a sensitivity range, and an audit trail. Your team can rerun scenarios without needing us in the room.
Fractional team, not a project hand-off.
Engagements run on an agreement with a regular cadence. Your team is in the build the whole way, so the model they end up with is one they helped shape.
Who we help
Where are you in the journey?
Ideation & pre-raise
Early stage: Is the pathway viable?
University spin-outs, incubator teams, and pre-VC companies working out whether there is defensible commercialisation value before committing further.
Read this stage →
Preparing to raise
Your next round will ask about reimbursement.
Series A and B companies who need a reimbursement pathway asset in the data room, built to withstand investor diligence.
Read this stage →
Preparing to submit
Build a dossier your payer can defend.
Approaching a NICE (United Kingdom), MSAC/PBAC (Australia), or Pharmac (New Zealand) submission. We run the HTA process as a team member, not a vendor.
Read this stage →
Expanding
One story, adapted for every market.
The structural work travels with you across markets. Each new jurisdiction is an adaptation of the model, the comparators, and the dossier, not a rebuild from scratch.
Read this stage →
Healthcare systems
The economic case for how you deliver care.
Hospital groups, integrated delivery networks, primary care networks, and telehealth programmes building the economic argument for new models of care.
For health systems →
Trusted by teams building globally
Affiliations
Newsletter
Reimbursement strategy, in your inbox.
Occasional notes on health economics methodology, HTA jurisdictions, and the commercial mechanics of reimbursement. No spam, unsubscribe anytime.
By subscribing you agree to our privacy policy. Confirmation email sent to you to verify the address.
A conviction we work from